Emergency contraception (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Emergency contraception" in English language version.

Last modified:

Ref.Un. Ref.Website
Global rank English rank
5th place
5th place
1st place
1st place
2nd place
2nd place
4th place
4th place
802nd place
528th place
15th place
8th place
low place
low place
low place
7,437th place
470th place
329th place
213th place
314th place
7th place
7th place
23rd place
15th place
62nd place
100th place
6th place
6th place
1,819th place
1,036th place
low place
low place
114th place
75th place
3,581st place
1,811th place
low place
low place
7,822nd place
low place
6,216th place
3,860th place
35th place
24th place
low place
9,403rd place
low place
low place
2,559th place
2,163rd place
2,128th place
1,157th place
4,048th place
2,846th place
2,191st place
1,798th place
251st place
248th place
4,892nd place
3,451st place
low place
low place
84th place
63rd place
1,078th place
916th place
low place
low place
207th place
347th place
407th place
286th place
202nd place
1,062nd place
352nd place
167th place
4,484th place
3,846th place
low place
low place

aafp.org (Global: 2,559th place; English: 2,163rd place)

acog.org (Global: low place; English: 9,403rd place)

archive.org (Global: 6th place; English: 6th place)

ca.gov (Global: 352nd place; English: 167th place)

pharmacy.ca.gov

cdc.gov (Global: 251st place; English: 248th place)

corporate-ir.net (Global: 4,484th place; English: 3,846th place)

phx.corporate-ir.net

doi.org (Global: 2nd place; English: 2nd place)

ec-ec.org (Global: low place; English: low place)

ellaone.com (Global: low place; English: low place)

europa.eu (Global: 62nd place; English: 100th place)

ema.europa.eu

reports.eea.europa.eu

fda.gov (Global: 470th place; English: 329th place)

fda.gov

accessdata.fda.gov

  • "Application Number: 21-045/S011 Medical Review" (PDF). Beltsville, Md.: Food and Drug Administration Center for Drug Evaluation and Research. August 22, 2006. pp. 32–7, 133–77. Retrieved 2006-12-13.
  • Duramed Pharmaceuticals/Barr Pharmaceuticals (now Teva Women's Health) (July 9, 2010). "Prescribing information: Plan B One-Step; 12.1 Mechanism of action" (PDF). Silver Spring, Md.: FDA Center for Drug Evaluation and Research (CDER). p. 4. Emergency contraceptive pills are not effective if a woman is already pregnant. Plan B One-Step is believed to act as an emergency contraceptive principally by preventing ovulation or fertilization (by altering tubal transport of sperm and/or ova). In addition, it may inhibit implantation (by altering the endometrium). It is not effective once the process of implantation has begun.
  • Watson Pharma (under license from HRA Pharma) (May 2, 2012). "Prescribing information: Ella; 12.1 Mechanism of action" (PDF). Silver Spring, Md.: FDA Center for Drug Evaluation and Research (CDER). pp. 4–5. Archived from the original (PDF) on June 8, 2015. When taken immediately before ovulation is to occur, ella postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation; however, alterations to the endometrium that may affect implantation may also contribute to efficacy... The pharmacodynamics of ulipristal acetate depends on the timing of administration in the menstrual cycle. Administration in the mid-follicular phase causes inhibition of folliculogenesis and reduction of estradiol concentration. Administration at the time of the luteinizing hormone peak delays follicular rupture by 5 to 9 days. Dosing in the early luteal phase does not significantly delay endometrial maturation but decreases endometrial thickness by 0.6 ± 2.2 mm (mean ± SD).

fpa.org.uk (Global: low place; English: low place)

fsrh.org (Global: low place; English: low place)

  • RCOG Faculty of Sexual; Reproductive Healthcare; Clinical Effectiveness Unit (January 2012). "Clinical guidance: emergency contraception" (PDF). Clinical Guidance. London: Royal College of Obstetricians and Gynaecologists. ISSN 1755-103X. Archived from the original (PDF) on 2012-05-26. Retrieved 2012-04-30. p.3:
    How does EC work?
    In 2002, a judicial review ruled that pregnancy begins at implantation, not fertilisation.8 The possible mechanisms of action should be explained to the patient as some methods may not be acceptable, depending on individual beliefs about the onset of pregnancy and abortion.
    Copper-bearing intrauterine device (Cu-IUD). Copper is toxic to the ovum and sperm and thus the copper-bearing intrauterine device (Cu-IUD) is effective immediately after insertion and works primarily by inhibiting fertilisation.9–11 A systematic review on mechanisms of action of IUDs showed that both pre- and postfertilisation effects contribute to efficacy.11 If fertilisation has already occurred, it is accepted that there is an anti-implantation effect,12,13
    Levonorgestrel (LNG). The precise mode of action of levonorgestrel (LNG) is incompletely understood but it is thought to work primarily by inhibition of ovulation.16,17
    Ulipristal acetate (UPA). UPA's primary mechanism of action is thought to be inhibition or delay of ovulation.2
  • "UK medical eligibility criteria for contraceptive use: Emergency contraception" (PDF). London: Royal College of Obstetricians and Gynaecologists Faculty of Sexual Reproductive Healthcare. 2009. pp. 107–115. Archived from the original (PDF) on 2016-03-03. Retrieved 2012-04-30.
  • RCOG Faculty of Sexual; Reproductive Healthcare; Clinical Effectiveness Unit (January 2012). "Clinical guidance: drug interactions with hormonal contraception" (PDF). Clinical Guidance. London: Royal College of Obstetricians and Gynaecologists. ISSN 1755-103X. Archived from the original (PDF) on 2012-05-26. Retrieved 2012-04-30.

gpo.gov (Global: 1,819th place; English: 1,036th place)

guttmacher.org (Global: low place; English: 7,437th place)

imb.ie (Global: low place; English: low place)

japantimes.co.jp (Global: 407th place; English: 286th place)

jstor.org (Global: 23rd place; English: 15th place)

mayoclinic.org (Global: 2,191st place; English: 1,798th place)

medicines.ie (Global: low place; English: low place)

medicines.org.uk (Global: 4,892nd place; English: 3,451st place)

  • Bayer (March 22, 2010). "Summary of Product Characteristics: Levonelle One Step 1500 mcg; 5.1 Pharmacodynamic properties". London: electronic Medicines Compendium (eMC), Datapharm. The precise mode of action of Levonelle One Step is not known. At the recommended regimen, levonorgestrel is thought to work mainly by preventing ovulation and fertilisation if intercourse has taken place in the preovulatory phase when the likelihood of fertilisation is the highest. It may also cause endometrial changes that discourage implantation. Levonelle One Step is not effective once the process of implantation has begun.
    HRA Pharma (July 19, 2011). "Summary of Product Characteristics: NorLevo 1.5 mg; 5.1 Pharmacodynamic properties". Dublin: Irish Pharmaceutical Healthcare Association. Archived from the original on June 15, 2012. Retrieved August 21, 2012. The precise mode of action of Norlevo 1.5 mg is not known. At the used regimen, levonorgestrel is believed to suppress ovulation thus preventing fertilization if the intercourse has taken place in the preovulatory phase when the likelihood of fertilization is the highest. It could also prevent implantation. It is not effective once the process of implantation has begun.

medscape.com (Global: 1,078th place; English: 916th place)

  • "Danazol". Medscape. 2002. Retrieved 2006-11-08.

motherjones.com (Global: 2,128th place; English: 1,157th place)

nature.com (Global: 207th place; English: 347th place)

  • "Sponsors". Fertility. 2002. Retrieved 2006-12-01.

nhk.or.jp (Global: 202nd place; English: 1,062nd place)

www3.nhk.or.jp

nih.gov (Global: 5th place; English: 5th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

nichd.nih.gov

npr.org (Global: 114th place; English: 75th place)

nytimes.com (Global: 7th place; English: 7th place)

pharmaceutical-journal.com (Global: low place; English: low place)

popsci.com (Global: 4,048th place; English: 2,846th place)

princeton.edu (Global: 802nd place; English: 528th place)

ec.princeton.edu

semanticscholar.org (Global: 15th place; English: 8th place)

api.semanticscholar.org

supremecourt.gov (Global: 3,581st place; English: 1,811th place)

time.com (Global: 84th place; English: 63rd place)

ucsf.edu (Global: 6,216th place; English: 3,860th place)

beyondthepill.ucsf.edu

washingtonpost.com (Global: 35th place; English: 24th place)

web.archive.org (Global: 1st place; English: 1st place)

who.int (Global: 213th place; English: 314th place)

who.int

whqlibdoc.who.int

  • "Emergency contraceptive pills (ECPs)" (PDF). Medical eligibility criteria for contraceptive use (4th ed.). Geneva: World Health Organization Department of Reproductive Health and Research. 2009. p. 63. ISBN 978-92-4-156388-8. Archived from the original (PDF) on Jul 14, 2015.
  • UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) (March 25, 2010). "Fact sheet on the safety of levonorgestrel-alone emergency contraceptive pills (LNG ECPs)" (PDF). Geneva: World Health Organization.
    Can LNG ECPs cause an abortion?
    LNG ECPs do not interrupt an established pregnancy or harm a developing embryo.15 The evidence available to date shows that LNG ECP use does not prevent a fertilized egg from attaching to the uterine lining. The primary mechanism of action is to stop or disrupt ovulation; LNG ECP use may also prevent the sperm and egg from meeting.16

womenshealth.gov (Global: 7,822nd place; English: low place)

worldcat.org (Global: 4th place; English: 4th place)

search.worldcat.org

  • Trussell J, Schwarz EB (2011). "Emergency contraception". In Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Kowal D, Policar MS (eds.). Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 113–145. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734. p. 121:
    Mechanism of action
    Copper-releasing IUCs
    When used as a regular or emergency method of contraception, copper-releasing IUCs act primarily to prevent fertilization. Emergency insertion of a copper IUC is significantly more effective than the use of ECPs, reducing the risk of pregnancy following unprotected intercourse by more than 99%.2,3 This very high level of effectiveness implies that emergency insertion of a copper IUC must prevent some pregnancies after fertilization.
    Emergency contraceptive pills
    To make an informed choice, women must know that ECPs—like the birth control pill, patch, ring, shot, and implant,76 and even like breastfeeding77—prevent pregnancy primarily by delaying or inhibiting ovulation and inhibiting fertilization, but may at times inhibit implantation of a fertilized egg in the endometrium. However, women should also be informed that the best available evidence indicates that ECPs prevent pregnancy by mechanisms that do not involve interference with post-fertilization events.
    ECPs do not cause abortion78 or harm an established pregnancy. Pregnancy begins with implantation according to medical authorities such as the US FDA, the National Institutes of Health79 and the American College of Obstetricians and Gynecologists (ACOG).80
    Ulipristal acetate (UPA). One study has demonstrated that UP can delay ovulation.81... Another study found that UPA altered the endometrium, but whether this change would inhibit implantation is unknown.82
    p. 122:
    Progestin-only emergency contraceptive pills. Early treatment with ECPs containing only the progestin levonorgestrel has been shown to impair the ovulatory process and luteal function.83–87
    p. 123:
    Combined emergency contraceptive pills. Several clinical studies have shown that combined ECPs containing ethinylestradiol and levonorgestrel can inhibit or delay ovulation.107–110
  • Trussell J (2019). "Chapter 10 Emergency Contraception". Contraceptive technology. Cleland, K; Schwarz, EB (21st ed.). New York: Ardent Media. pp. 329–356. ISBN 978-1-7320556-0-5. OCLC 1048947218.
  • RCOG Faculty of Sexual; Reproductive Healthcare; Clinical Effectiveness Unit (January 2012). "Clinical guidance: emergency contraception" (PDF). Clinical Guidance. London: Royal College of Obstetricians and Gynaecologists. ISSN 1755-103X. Archived from the original (PDF) on 2012-05-26. Retrieved 2012-04-30. p.3:
    How does EC work?
    In 2002, a judicial review ruled that pregnancy begins at implantation, not fertilisation.8 The possible mechanisms of action should be explained to the patient as some methods may not be acceptable, depending on individual beliefs about the onset of pregnancy and abortion.
    Copper-bearing intrauterine device (Cu-IUD). Copper is toxic to the ovum and sperm and thus the copper-bearing intrauterine device (Cu-IUD) is effective immediately after insertion and works primarily by inhibiting fertilisation.9–11 A systematic review on mechanisms of action of IUDs showed that both pre- and postfertilisation effects contribute to efficacy.11 If fertilisation has already occurred, it is accepted that there is an anti-implantation effect,12,13
    Levonorgestrel (LNG). The precise mode of action of levonorgestrel (LNG) is incompletely understood but it is thought to work primarily by inhibition of ovulation.16,17
    Ulipristal acetate (UPA). UPA's primary mechanism of action is thought to be inhibition or delay of ovulation.2
  • RCOG Faculty of Sexual; Reproductive Healthcare; Clinical Effectiveness Unit (January 2012). "Clinical guidance: drug interactions with hormonal contraception" (PDF). Clinical Guidance. London: Royal College of Obstetricians and Gynaecologists. ISSN 1755-103X. Archived from the original (PDF) on 2012-05-26. Retrieved 2012-04-30.
  • Dean G, Schwarz EB (2019). Contraceptive technology—Chapter 5—Intrauterine Devices (IUDs) (21st ed.). New York, NY. p. 159. ISBN 978-1-7320556-0-5. OCLC 1048947218.{{cite book}}: CS1 maint: location missing publisher (link)